TFF Pharmaceuticals Announced Its New Partnership With Emory University And The Biomedical Advanced Research And Development Authority To Develop A Dry Powder Inhaled Mrna-based Treatment For Influenza And Covid
Portfolio Pulse from Benzinga Newsdesk
TFF Pharmaceuticals has partnered with Emory University and the Biomedical Advanced Research and Development Authority to develop a dry powder inhaled mRNA-based treatment for influenza and COVID-19.
September 11, 2024 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TFF Pharmaceuticals has entered a partnership with Emory University and BARDA to develop a dry powder inhaled mRNA-based treatment for influenza and COVID-19, potentially enhancing its product portfolio and market position.
The partnership with Emory University and BARDA is significant as it involves developing a novel mRNA-based treatment, which could enhance TFF Pharmaceuticals' product offerings and market competitiveness. This development is likely to positively impact TFFP's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100